Phosphodiesterase 5 inhibitors and cystic fibrosis: correcting chloride channel dysfunction.
Clarke
Lane L
LL
D000818:Animals; D002712:Chlorides / Q000378:metabolism*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000378:metabolism; D004195:Disease Models, Animal; D007093:Imidazoles / Q000493:pharmacokinetics*; D008564:Membrane Potentials / Q000187:drug effects*; D051379:Mice; D018181:Mice, Inbred CFTR; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000493:pharmacokinetics*; D010879:Piperazines / Q000493:pharmacokinetics*; D046188:Protein Modification, Translational / Q000187:drug effects; D011687:Purines / Q000493:pharmacokinetics; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000493:pharmacokinetics*; D014227:Triazines / Q000493:pharmacokinetics; D000069058:Vardenafil Dihydrochloride
D002712:Chlorides; D007093:Imidazoles; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014227:Triazines; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D000069058:Vardenafil Dihydrochloride; D000068677:Sildenafil Citrate